Dr. Sandra Kweder, the deputy director of the FDA's Office of New Drugs, said that many of Horton's assertions were "flat-out wrong." ``We don't always understand the full magnitude of a drug's risks before it goes on the market,'' said Steven Galson, acting director of the FDA's Center for Drug Evaluation and Research, in a teleconference on the new initiatives.
The position has been vacant for more than a year.
Sen. Chuck Grassley, R-Iowa, chairman of the Senate Committee on Finance and recently a sharp critic of the FDA's actions, called the announcement ``welcome, albeit late in coming.'' In a
